Publications

ATCHIVR has a mandate to encourage research both from fellows and staff to capacitate the community on various aspect including and not limited to Bioinformatics, Biostatistics, Data Science and Data management, TB and HIV. 

Dolutegravir drug-resistance monitoring in Africa.

Kouamou V, Inzaule S, Manasa J.

PMID: 34735801, DOI: 10.1016/S2352-3018(21)00268-X

View Article

Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.
SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe.
HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.

Amanda Madyadi 1 2Milcah Dhoro 2Tinei Shamu 3 4 5Tendai Washaya 1Vinie Kouamou 2Benjamin Chimukangara 6 7 8David Katzenstein 1 9Justen Manasa 2

PMID: 34714124, PMCID: PMC8817709 (available on ), DOI: 10.1089/AID.2021.0084

View Article

Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe.
Effects of repeated blood donation on iron status of blood donors in Zimbabwe: A cross-sectional study.
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
The transient effect of a peer support intervention to improve adherence among adolescents and young adults failing antiretroviral therapy in Harare, Zimbabwe: a randomized control trial
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy
Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries
Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?